Incruse Ellipta (umeclidinium) Disease Interactions
There are 2 disease interactions with Incruse Ellipta (umeclidinium):
Inhaled Anticholinergic Bronchodilators (Includes Incruse Ellipta) ↔ Milk Protein Allergies
Severe Potential Hazard, Moderate plausibility
Applies to: Lactose Intolerance
Some inhaled anticholinergic bronchodilators such as aclidinium and umeclidinium are contraindicated in patients with severe hypersensitivity to milk proteins. There have been reports of anaphylactic reactions on these patients after inhalation of other powder products containing lactose, therefore patients with severe milk protein allergy should not use these products.
Umeclidinium (Includes Incruse Ellipta) ↔ Severe Liver Impairment
Moderate Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Patients with moderate hepatic impairment showed no relevant increases in Cmax or AUC when using umeclidinium, when compared with healthy subjects. However, studies have not been performed in patients with severe hepatic impairment.
Incruse Ellipta (umeclidinium) drug Interactions
There are 365 drug interactions with Incruse Ellipta (umeclidinium)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.